2025 年 21 巻 2 号 p. 170-174
Heart failure is a critical global public health issue, significantly impacting patients' quality of life and healthcare costs. In Japan, heart diseases rank among the leading causes of death, highlighting the urgent need for effective treatment strategies for heart failure patients. In recent years, guideline-directed medical therapy (GDMT) has been increasingly recommended, with particular focus on the use and optimization of specific therapeutic agents. Our study demonstrated that the reinforcement of GDMT in heart failure patients receiving pimobendan may contribute to a reduction in rehospitalization rates. This effect was particularly pronounced in patients with reduced ejection fraction (rEF), emphasizing the pivotal role of GDMT in heart failure management. This article explores the impact of the combination of pimobendan and GDMT on the prognosis of patients with heart failure.